Daily PubMed evidence board
Percutaneous thermal ablation versus robot-assisted partial nephrectomy for localized renal cell carcinoma: a systematic review and meta-analysis stratified by tumor complexity.
This systematic review and meta-analysis compared robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA) for localized kidney c…
Signal score64Research triage score
CertaintyModerateVerify in full text
PMID42223755Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis compared robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA) for localized kidney cancer and looked at how tumor complexity affects outcomes. Across 17 studies with 2,516 patients, PTA patients were older and sicker. PTA had a higher rate of local tumor recurrence and a higher chance of technical failure at first treatment (~11%). RAPN lowered the risk of recurrence overall. Major complications and changes in kidney function were similar between the two approaches, and long-term survival outcomes did not differ significantly. The authors conclude RAPN gives better local tumor control, including for complex tumors, while PTA remains reasonable for carefully selected high-risk patients but requires close follow-up for recurrence.
Why it matters
- Compares two established local therapies for localized renal cell carcinoma (RCC): robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA), informing surgical versus minimally invasive management choices.
- Stratifies results by tumor complexity (RENAL/PADUA scores) - a clinically relevant modifier that could change treatment selection for anatomically complex renal lesions.
- Finds higher local recurrence with PTA but similar long-term survival and renal function, which affects surveillance strategies and shared decision-making, especially for older or comorbid patients who are more likely to receive PTA.
Primary outcomes
- Local recurrence (LR)
- Recurrence-free survival (RFS)
- Metastasis-free survival (MFS)
- Cancer-specific survival (CSS)
- Overall survival (OS)
Effect summary
Abstract-reported results: PTA associated with higher pooled local recurrence (pooled logRR 0.97, 95% CI 0.65 to 1.28) and primary technical failure rate of first PTA ~10.9%. RAPN associated with lower hazard of recurrence overall (pooled logHR -0.92, 95% CI -1.29 to -0.56); difference in recurrence HR did not reach significance in intermediate-high complexity subgroup (pooled logHR -0.75, 95% CI -1.6 to 0.1). No significant differences in major complications or short- and long-term eGFR variation; no differences in metastatic progression, cancer-specific survival, or overall survival reported in abstract.
Benefit-cost lens
| Quick take | RAPN provides better local tumor control than PTA without higher major complications or worse renal function; PTA remains an option for high-risk surgical candidates but requires more intensive surveillance. Benefit-cost claims need absolute risks, costs, and target population size for local decision-making. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based solely on PubMed metadata and abstract; full-text methods, patient selection, follow-up duration, and absolute event rates must be verified before economic or clinical implementation. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based on abstract only. The included studies are likely observational/comparative cohorts with baseline differences (PTA patients older and more comorbid), which raises confounding risk. Full-text is required for formal RoB appraisal (study-level bias, selection, confounding control, heterogeneity, publication bias). |
Harms, equity, conflicts & implementation
| Implementation | Full-text review; extraction of absolute event rates and follow-up duration; local cost and capacity assessment for RAPN vs PTA; multidisciplinary stakeholder review (urology, interventional radiology, nephrology); surveillance protocols for PTA recipients; consideration of patient fitness and tumor complexity scoring. |
|---|---|
| Equity impact | Unclear from abstract. Potential equity issues if access to RAPN (robotic surgery) is limited in some centers or if PTA is preferentially used in older/comorbid populations; subgroup reporting in full text needed. |
| Harms | Abstract reports no significant difference in major complications between techniques; however, PTA had ~10.9% primary technical failure requiring additional treatment. Full-text needed for detailed adverse event profiles and re-intervention rates. |
| Replication | Unknown from abstract/metadata; replication would require access to included studies and re-analysis of pooled data. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.